 |
|
Epstein-Barr Virus and Multiple SclerosisEvidence of Association From a Prospective Study With Long-term Follow-up
Gerald N. DeLorenze, PhD;
Kassandra L. Munger, MSc;
Evelyn T. Lennette, PhD;
Norman Orentreich, MD;
Joseph H. Vogelman, DEE;
Alberto Ascherio, MD, DrPH
Arch Neurol. 2006;63:839-844. Published online April 10, 2006 (doi:10.1001/archneur.63.6.noc50328).
Objective To determine whether serum titers of anti–Epstein-Barr virus (EBV) antibodies are elevated in blood specimens collected up to 30 years prior to onset of multiple sclerosis (MS).
Methods Individuals with MS were identified among members of the Kaiser Permanente Northern California health plan who participated in the multiphasic examinations administered between 1965 and 1974. Stored serum samples were used to compare anti-EBV antibody titers in 42 individuals who developed MS with age-matched and sex-matched controls.
Results The geometric mean titers of antibodies to the Epstein-Barr nuclear antigen (EBNA) complex and its component EBNA-1 were significantly higher in the MS cases when compared with matched controls. The relative risk of MS associated with a 4-fold increase in antibody titers was 2.1 (95% confidence interval, 1.1-3.8) for the EBNA complex and 1.8 (95% confidence interval, 1.1-2.9) for EBNA-1. Elevations of antibody titers to the EBNA complex and EBNA-1 among MS cases first occurred between 15 to 20 years before the onset of symptoms and persisted thereafter.
Conclusion The elevation of anti-EBV titers is probably an early event in the pathogenesis of MS and is unlikely to be the result of an aspecific immune dysregulation.
Author Affiliations: Kaiser Permanente Division of Research, Oakland, Calif (Dr DeLorenze); Departments of Nutrition (Dr Ascherio and Ms Munger) and Epidemiology (Dr Ascherio), Harvard School of Public Health, and Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School (Dr Ascherio), Boston, Mass; Virolab Inc, Berkeley, Calif (Dr Lennette); Orentreich Foundation for the Advancement of Science Inc, New York, NY (Drs Orentreich and Vogelman).
RELATED ARTICLE
Epstein-Barr Virus and Multiple Sclerosis
Amy E. Lovett-Racke and Michael K. Racke
Arch Neurol. 2006;63(6):810-811.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis
Jilek et al.
Brain 2008;131:1712-1721.
ABSTRACT
| FULL TEXT
Herpesviruses and human endogenous retroviral sequences in the cerebrospinal fluid of multiple sclerosis patients
Alvarez-Lafuente et al.
Mult Scler 2008;14:595-601.
ABSTRACT
When one and one make three: HLA and EBV infection in MS
Marrie
Neurology 2008;70:1067-1068.
FULL TEXT
Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis
De Jager et al.
Neurology 2008;70:1113-1118.
ABSTRACT
| FULL TEXT
The association of multiple sclerosis and Hodgkin's disease: the role of Epstein--Barr virus infection
Habek et al.
Mult Scler 2008;14:284-287.
ABSTRACT
Common infectious agents in multiple sclerosis: a case control study in children
Krone et al.
Mult Scler 2008;14:136-139.
ABSTRACT
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain
Serafini et al.
J. Exp. Med. 2007;204:2899-2912.
ABSTRACT
| FULL TEXT
Epstein-Barr Virus: Environmental Trigger of Multiple Sclerosis?
Lunemann et al.
J. Virol. 2007;81:6777-6784.
FULL TEXT
Correlations between Epstein-Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals
Nielsen et al.
Mult Scler 2007;13:420-423.
ABSTRACT
Brains and peripheral blood mononuclear cells of multiple sclerosis (MS) patients hyperexpress MS-associated retrovirus/HERV-W endogenous retrovirus, but not Human herpesvirus 6
Mameli et al.
J. Gen. Virol. 2007;88:264-274.
ABSTRACT
| FULL TEXT
High seroprevalence of Epstein-Barr virus in children with multiple sclerosis
Pohl et al.
Neurology 2006;67:2063-2065.
ABSTRACT
| FULL TEXT
Epstein-Barr virus and multiple sclerosis.
Lovett-Racke and Racke
Arch Neurol 2006;63:810-811.
FULL TEXT
|
